B
Brian Bettencourt
Researcher at Alnylam Pharmaceuticals
Publications - 96
Citations - 3700
Brian Bettencourt is an academic researcher from Alnylam Pharmaceuticals. The author has contributed to research in topics: RNA interference & Gene. The author has an hindex of 21, co-authored 95 publications receiving 3140 citations.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Teresa Coelho,David H. Adams,Ana Martins da Silva,Pierre Lozeron,Philip N. Hawkins,Timothy Mant,Javier Perez,Joseph Chiesa,Steve Warrington,Elizabeth Tranter,Malathy Munisamy,Rick Falzone,Jamie Harrop,Jeffrey Cehelsky,Brian Bettencourt,Mary Geissler,James Butler,Alfica Sehgal,Rachel Meyers,Qingmin Chen,Todd Borland,Renta Hutabarat,Valerie A. Clausen,Rene Alvarez,Kevin Fitzgerald,Christina Gamba-Vitalo,Saraswathy V. Nochur,Akshay Vaishnaw,Dinah W.Y. Sah,Jared Gollob,Ole B. Suhr +30 more
TL;DR: A therapeutic approach mediated by RNA interference (RNAi) could reduce the production of transthyretin in peripheral nerves and the heart as mentioned in this paper, which is caused by the deposition of hepatocyte-derived tranthymretin amyloid in peripheral nerve and heart.
Journal ArticleDOI
A highly durable RNAi therapeutic inhibitor of PCSK9
Kevin Fitzgerald,Suellen White,Anna Borodovsky,Brian Bettencourt,Andrew Strahs,Valerie A. Clausen,Peter L.J. Wijngaard,Jay D. Horton,Jorg Taubel,Ashley Brooks,Chamikara Fernando,Robert S. Kauffman,David Kallend,Akshay Vaishnaw,Amy Simon +14 more
TL;DR: Doses of 300 mg or more (in single or multiple doses) significantly reduced levels of PCSK9 and LDL cholesterol for at least 6 months, and no serious adverse events were observed with inclisiran.
Journal ArticleDOI
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald,Maria Frank-Kamenetsky,Svetlana Shulga-Morskaya,Abigail Liebow,Brian Bettencourt,Jessica E. Sutherland,Renta Hutabarat,Valerie A. Clausen,Verena Karsten,Jeffrey Cehelsky,Saraswathy V. Nochur,Victor Kotelianski,Jay D. Horton,Timothy Mant,Joseph Chiesa,JM Ritter,Malathy Munisamy,Akshay Vaishnaw,Jared Gollob,Amy Simon +19 more
TL;DR: The results suggest that inhibition of PCSK9 synthesis by RNA interference (RNAi) provides a potentially safe mechanism to reduce LDL cholesterol concentration in healthy individuals with raised cholesterol.
Journal ArticleDOI
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
Ole B. Suhr,Teresa Coelho,Juan Buades,Jean Pouget,Isabel Conceição,John L. Berk,Hartmut Schmidt,Márcia Waddington-Cruz,Josep M. Campistol,Brian Bettencourt,Akshay Vaishnaw,Jared Gollob,David Adams +12 more
TL;DR: Patisiran was generally well tolerated and resulted in significant dose-dependent knockdown of transthyretin protein in patients with FAP, and is currently in phase III development.
Journal ArticleDOI
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe -/- mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia
Paul J. Schmidt,Ivanka Toudjarska,Anoop K. Sendamarai,Tim Racie,Stuart Milstein,Brian Bettencourt,Julia Hettinger,David Bumcrot,Mark D. Fleming +8 more
TL;DR: In this article, lipid nanoparticles (LNPs) were used to formulate Tmprss6 siRNA to increase hepatic expression of the iron-regulatory hormone hepcidin.